MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells

Abstract

Triple-negative breast cancer (TNBC) is the most common type of cancer among females worldwide and is associated with poor prognosis. Poly ADP-ribose polymerase-1 (PARP1) inhibitors are effective against TNBC with mutations in the breast cancer type 1 susceptibility protein (BRCA1) and/or BRCA2 genes; however, the development of resistance to PARP1 inhibitors limits their use. Thus, identifying strategies to overcome this resistance is urgently required. The aim of the present study was to investigate the potential function and mechanism of small interfering (si)RNA-MAPK4 (siMAPK4) in enhancing the efficacy of a PARP1 inhibitor and reducing the resistance. In the present study, data on the mRNA expression level of MAPK4 in normal breast tissues and TNBC tissues were obtained from The Cancer Genome Atlas database. The mRNA and protein expression levels of MAPK4 in normal breast cells and TNBC cells were analyzed using reverse transcription-quantitative PCR and western blotting, respectively. The phosphorylated (p) histone H2AX (γH2AX) protein expression was assessed via immunofluorescence. Cell Counting Kit-8, wound healing and TUNEL assays were used to determine the proliferative, migratory and apoptotic abilities of HCC1937 cells. MAPK4 was highly expressed in TNBC patient tissues and cell lines. Moreover, overexpression of MAPK4 could promote HCC1937 cell proliferation. Treatment of HCC1937 cells with the combination of siMAPK4 and a PARP1 inhibitor olaparib decreased their proliferation and migration and increased their apoptosis. The protein expression levels of the DNA repair-related proteins p-DNA-dependent protein kinase catalytic subunit (DNA-PK) and RAD51 recombinase (RAD51) were inhibited in the siMAPK4 and siMAPK4 + olaparib groups. However, the marker of a double-stranded break γH2AX showed increased protein expression in the siMAPK4 + olaparib group. As MAPK4 could phosphorylate AKT at threonine 308 (AKT T308 ), the current study restored p-AKT T308 using a constitutively active AKT plasmid (AKT-CA). p-DNA-PK and RAD51 showed high expression and γH2AX exhibited lower protein expression in the AKT-CA group. The present findings suggested that siMAPK4 can enhance the sensitivity of TNBC cells to PARP1 inhibitors.

The silencing of miR-199a-5p protects the articular cartilage through MAPK4 in osteoarthritis

“…Structurally, MAPK4 lacks the Thr-X-Tyr activation motif, but contains the SEG (single exon gene) sequence and SPR motif, and thus cannot be phosphorylated by dual Ser/Thr and Tyr MAPK kinase (23,26,27). Research has shown the significance of MARK in the progression of several diseases, including prostate cancer (28), triple negative breast cancer (29), and cervical cancer (23). Additionally, MAPK4 could serve as a new modulator of acute lung injury (30).…”

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer

“…Interestingly, recent work suggests that ERK3 and ERK4 signaling may play a role with cancer initiation and progression. Specifically, it has been proposed that ERK4 promotes cancer progression via the non-canonical activation of AKT/mTOR signaling [17][18][19][20]. In order to investigate the role of ERK4 in TNBC, Wang et al [21] surveyed a panel of TNBC cell lines and found that ERK4 is highly expressed in MDA-MB-231, Hs578T and HCC1937 cell lines (referred to as MAPK4-high), while other TNBC cell lines express low-to-undetectable levels of the kinase.…”